EU New Drug Approvals Hit Record High
Total Includes Seven COVID-19 Products
Executive Summary
Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.
You may also be interested in...
Confronting The Challenges Of Marketing Cell And Gene Therapies
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
Coronavirus Notebook: Australia OKs Paxlovid, Lagevrio & Nuvaxovid, New Sputnik Data Show ‘Strong Protection’ Against Omicron
International regulators have broadened their discussions on the possible use of bivalent and multivalent vaccines, and the French presidency of the Council of the EU has called for “international solidarity” on vaccine provision.
IP Questions Could Dog The WHO's BioHub Pandemic Project
The World Health Organization’s BioHub project is gathering momentum, with the spotlight on the equitable and timely sharing of viruses and other biological materials to develop medical products for use in future health emergencies such as a pandemic. But while its objectives are lauded by many, concerns have been raised about the intellectual property implications of the project.